
ArcticZymes Investor Relations Material
Latest events

Q1 2025
ArcticZymes
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from ArcticZymes Technologies
Access all reports
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and markets recombinant enzymes derived from cold-water marine species and organisms from other relevant environments for use in molecular research, in vitro diagnostics, and therapeutics in Norway, Europe, Asia, Australia, Africa, and the Americas. It provides enzymes for real-time PCR; enzymes for various applications; Norzym Taq DNA Polymerase for routine PCR applications; Menthazym Taq DNA Polymerase that enables amplification of DNA in low-copy templates; Toyzym Taq DNA Polymerase that enhances PCR sensitivity and specificity; MgGapFill DNTP Mix that produces more reliable qPCR results by maximizing efficiency and reducing nonspecific amplifications; and ZymoTaq Hotstart qPCR Mix that provides speed and convenience with the increased specificity of hot-start chemistry.
Key slides for ArcticZymes Technologies


Nordic Small & Mid Cap Seminar 2025 Presentation
ArcticZymes Technologies


Nordic Small & Mid Cap Seminar 2025 Presentation
ArcticZymes Technologies
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
AZT
Country
🇳🇴 Norway